Fortaleza Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Fortaleza Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-35	Closed	-$3K	–	148
2016 Q4	$3K	Hold	35	–	–	0.01%	174
2016 Q3	$3.24K	Hold	35	–	–	﹤0.01%	186
2016 Q2	$3K	Buy	+35	New	+$2.98K	﹤0.01%	166
2016 Q1	–	Sell	-20	Closed	-$2K	–	190
2015 Q4	$2K	Hold	20	–	–	﹤0.01%	188
2015 Q3	$2K	Buy	+20	New	+$2.67K	﹤0.01%	181

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fortaleza Asset Management's BMRN Position: Q1 2017 in Review

Fortaleza Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 35 shares — an estimated $3K sold.

Fortaleza Asset Management first reported a position in BMRN in Q3 2015 and held it in 5 quarters. The position peaked at $3.24K in Q3 2016. 417 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

Fortaleza Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Fortaleza Asset Management sold 35 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $3K.
Fortaleza Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2015 and held it in 5 quarters.
Fortaleza Asset Management's BioMarin Pharmaceuticals position peaked at $3.24K in Q3 2016.
417 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Fortaleza Asset Management's 13F filing for Q1 2017, filed 5 May 2017.